Boston, MA 10/01/2013 (wallstreetpr) – On September 30, CytRx Corporation (NASDAQ:CYTR) announced results from its Phase 2 test it had conducted on cancer patients to address soft tissue sarcoma. The results showed that patients treated with target drug “aldoxorubicin” had responded better to treatment by over 22% as compared to their responses when treated by existing traditional chemotherapy agent doxorubicin. The target drug was also found to spread in an improved but narrow and focused range with in the human body in pharmacokinetics trial. The company additionally highlighted the better survival rates among animals which were treated by “aldoxorubicin” in comparison to being treated by doxorunicin.
Modalities of the test’s conducted
These positive responses from the Phase 2b clinical trials was based on independent radiology observations in a “blinded reading of tumour scans” of patients who were being treated by administering “aldoxorubicin” at 3.5 times dosage in comparison to doxorubicin.
The announcements from yesterday further disclosed that treatments based on “Glioblastoma Model” had revealed significant improvement in survival rates. This test related to human glioblastoma cells being implanted in the brain of “immunologically deficient” mice. These subject mice were observed to survive 63 days more when treated by “aldoxorubicin”. In comparison these animals lasted only 25 days when they were treated by doxorubicin.
CytRx announced launch of two new Phase 2 trails
Based on the positive outcomes from these above trials, the company has gone ahead and registered with FDA for expanding trials on 28 patients suffering from “unresectable glioblastoma” and have not responded to treatment from traditional drug “temozolomide”. The firm also announced its intentions to start phase 2 clinical trials over the next three months to evaluate the efficacy of treating patients suffering from AIDS induced Kaposi sarcoma with “aldoxorubicin”
The company stock saw its value drop by over 4.44% during trading on September 30 in spite of positive news from its Phase 2 trails.
